Galectin Therapeutics Inc.'s board elected Richard Uihlein to be the healthcare company's chairman.
Uihlein, who replaces Marc Rubin, will be joined by Kevin Freeman, who was elected vice chairman of the Norcross, Ga.-based company.
Uihlein will be leading the company as it advances GR-MD-02 for the potential treatment of non-alcoholic steatohepatitis cirrhosis, the final stage of the liver disease that affects millions of people in the U.S. and worldwide, according to the company.
Uihlein has been a Galectin director since 2017 and is a long-time investor in the company. He is a co-founder of Uline Inc., a distributor of shipping, packaging and industrial supplies, serving as its CEO and chairman since its 1980 inception.
